Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.41 |
| ▸ | CDK1 | P06493 | 2/20 | 0.41 |
| ▸ | CDK4 | P11802 | 2/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.41 |
| ▸ | CCND1 | P24385 | 2/20 | 0.41 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.39 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2524154 | 0.84 | L3MBTL1 (0.52) | MAOAMAOBMAPTL3MBTL1RAB9A | |
| SCHEMBL13754873 | 0.83 | GRM5 (0.41) | MAOBL3MBTL1TRPV3PKMGRM5 | |
| SCHEMBL29056065 | 0.81 | TERT (0.44) | NPC1GRM5 | |
| SCHEMBL9756829 | 0.80 | KDM4E (0.53) | PKM | |
| SCHEMBL9756831 | 0.80 | KDM4E (0.53) | PKM | |
| SCHEMBL12523548 | 0.78 | MAOB (0.41) | MAOAMAOBMAPTL3MBTL1RAB9A | |
| SCHEMBL13059001 | 0.78 | TRPV3 (0.49) | MAOAMAOBMAPTL3MBTL1NPC1 | |
| SCHEMBL29432773 | 0.77 | BTK (0.49) | MAOAMAPTNPC1RAB9AMAPK1 | |
| SCHEMBL1536655 | 0.77 | BTK (0.49) | MAOAMAPTNPC1RAB9AMAPK1 | |
| SCHEMBL24754816 | 0.76 | TRPV3 (0.57) | MAOBMAPTL3MBTL1TRPV3PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118271299-A | Lactam compound, and preparation method and application thereof | 广州市联瑞制药有限公司 | 2024-07-02 | — | — | CN | disclosed |
| US-9012651-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2015-04-21 | — | — | US | disclosed |
| WO-2012129491-A1 | TRPV3 MODULATORS | ABBOTT LABORATORIES (US) | 2012-09-27 | — | — | WO | disclosed |
| US-20120245124-A1 | TRPV3 Modulators | ABBOTT LABORATORIES (US) | 2012-09-27 | — | — | US | disclosed |
| US-20060106070-A1 | Novel pyridine-based metal chelators as antiviral agents | BIOFLEXIS, LLC (US) | 2006-05-18 | — | — | US | disclosed |
| US-20060100282-A1 | Novel diaminopropane-based metal chelators as antiviral agents | BIOFLEXIS, LLC (US) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245124-A1 | TRPV3 Modulators | TRPV3, TRPV2, TRPV1 | MAOA 3476/4885MAOB 3078/4885MAPT 3335/4885 |
| US-20060106070-A1 | Novel pyridine-based metal chelators as antiviral agents | SLC39A7, SLC7A1, SLC30A7 | MAOA 1146/4885MAOB 445/4885MAPT 4358/4885 |
| US-20060100282-A1 | Novel diaminopropane-based metal chelators as antiviral agents | SLC7A1, AOC1, APEH | MAOA 800/4885MAOB 463/4885MAPT 4840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.